DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Oncology Homepage

New PET imaging method may yield benefits over FDG for detecting certain cancers Gallium-68-labeled FAPI tracer yields promising results

Dr. Carri Glide-Hurst American Association of Physicists in Medicine elects fellow

Cecilia Danckwardt-Lillieström C-RAD appoints new CFO

Fox Chase Cancer Center gets $673K grant to develop early-stage lung cancer test Taking aim at false positive CT lung scans

Radiotherapy may cause gaps in memory recall for children, says study Trouble recalling specifics of events after treatment

New brachytherapy approach deemed safe for clinical trials First alpha radiation-based cancer treatment for solid tumors

Radiotherapy vacancies rise above three percent, says ASRT survey Vacancies highest in Pacific region of U.S.

AI model strikes balance between dose toxicity and tumor reduction Minimizes dose while still shrinking tumor

Guerbet teams with Imalogix to enhance dose management Utilizes Imalogix's AI-based process and workflow solutions

Particle accelerator... on a chip? Setting the stage for a new generation of ‘tabletop’ accelerators

Israeli startup Alpha Tau Medical raises $29 million for novel radiotherapy

by Thomas Dworetzky , Contributing Reporter
Alpha Tau Medical, developer of Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT), has raised $29 million in private money in a round led by Israeli private equity firm Shavit Capital.

The late-stage investor was part of a round that included crowdfunding platform OurCrowd.com, Medison Ventures, and Sir Ronald Cohen and Alan Patricof, founders of Apax Partners.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



"We are excited by the strong support provided by these distinguished investors," Alpha Tau's CEO Uzi Sofer said in a statement. "The funding will be invaluable to explore the full potential of the Alpha DaRT as a cancer treatment for clinical trials worldwide, as well as establish global production facilities for the radioactive DaRT seeds to meet local distribution demand."

The investment comes on the heels of the Massachusetts Radiation Control Program (RCP), in conjunction with the U.S. Nuclear Regulatory Commission (NRC), approving Alpha DaRT cancer treatment as a Sealed Source and Device (SSD), and safe for clinical trials.

It is the first alpha radiation-based cancer treatment for various types of solid tumors, administering high-precision, soft-range alpha particles that effectively destroy cancer cells while sparing surrounding healthy tissue.

The particles are inserted into the tumor using ultra-minimally-invasive applicators created to reach various types of tumors in different anatomic areas.

As the radioactive material inside decays, it releases alpha radiation inside the tumor, breaking the DNA in ways that destroy cancer cells.

“The Alpha DaRT applicators are designed to ensure that the Alpha DaRT seeds and the radioactive isotopes will be released only inside of the tumor in a way that will eliminate the risk of unnecessary exposure to the patient or the medical staff,” Amnon Gat, chief operations officer for Alpha Tau Medical, told HCB News in August. “The sealing mechanisms of the Alpha DaRT devices were tested under extreme environmental conditions that are required by ISO 2919, such as high temperature, pressure, impact and bending."

Early clinical trials have shown that Alpha DaRT is safe and effective for squamous cell carcinoma tumors – with all patients seeing tumor reduction and over 70 percent having tumors disappear within days of therapy.

"We are confident that Alpha Tau's groundbreaking technology can be a game changer in the treatment of cancer,”said Shavit Capital founder and managing partner Gary Leibler, stressing that the firm's experienced team had succeeded in forming “strategic relationships and trials with leading international medical research centers,” which position it to become a global power in next-gen cancer radiation therapies.

Meir Jakobsohn, the founder and CEO of Medison Pharma – one of the firm's first investors – added that his firm was “very optimistic about the Alpha DaRT's potential to activate the immune system and to become a valid treatment option for metastatic cancer.”

Clinical trials are now underway for Alpha DaRT using varied protocols across a number of cancers, including pancreatic, breast, head and neck, gynecological, and prostate.

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED